Group 1 - The core point of the article is the transfer of shares of Huakang Biomedical (08622) from Qingtian Securities to Jinlifeng Securities, with a market value of HKD 54.83 million, representing 27.74% of the total shares [1] - On October 9, Huakang Biomedical and the offeror Anselme Limited announced a conditional agreement for the sale of 138.7 million shares, which constitutes approximately 27.71% of the company's total issued share capital as of the announcement date [1] - The total consideration for the shares is HKD 17.47 million, equating to a price of HKD 0.126 per share [1]

Group 1 - The core point of the announcement is that Anselme Limited, as the buyer, has entered into a conditional sale agreement with seller Li Jingyang to acquire 138.7 million shares of Huakang Biomedical, representing approximately 27.71% of the company's total issued share capital, for a total consideration of HKD 17.4727 million, equating to HKD 0.126 per share [1] - Following the completion of the transaction, the buyer will directly and beneficially own 121 million shares, which is about 24.13% of the total issued share capital of the company [1] - After the completion of the transaction, the buyer, Dr. Zhou and any parties acting in concert with them will collectively own 259 million shares, representing approximately 51.84% of the total issued share capital [1][2] Group 2 - The offer price of HKD 0.126 per share represents a discount of approximately 68.10% compared to the closing price of HKD 0.395 per share on the date of the announcement [1] - The company has applied to the Stock Exchange for the resumption of trading of its shares on GEM starting from 9:00 AM on October 10, 2025 [3]

Group 1 - The core point of the announcement is that Anselme Limited, as the buyer, has entered into a conditional sale agreement with seller Li Jingyang to acquire 138.7 million shares of Huakang Biomedical, representing approximately 27.71% of the company's total issued share capital, for a total consideration of HKD 17.4727 million, equating to HKD 0.126 per share [1] - Following the completion of the transaction, the buyer will directly and beneficially own 121 million shares, which is about 24.13% of the total issued share capital of the company [1] - After the completion of the transaction, the buyer, Dr. Zhou and any parties acting in concert with them will collectively own 259 million shares, representing approximately 51.84% of the total issued share capital of the company [1] Group 2 - The buyer is wholly owned by Dr. Zhou Xun Yong, who is also the sole director of the buyer [2] - The company has applied to the Stock Exchange for the resumption of trading of its shares on GEM starting from 9:00 AM on October 10, 2025 [2]

Core Viewpoint - The announcement details a conditional sale agreement between Anselme Limited (the offeror) and Li Jingyang (the seller) for the acquisition of 138.7 million shares of Huakang Biomedical, representing approximately 27.71% of the company's total issued share capital, for a total consideration of HKD 17.4727 million, equating to HKD 0.126 per share, which is a discount of about 68.10% compared to the market price on the announcement date [1][2]. Group 1 - The offeror will acquire 138.7 million shares, representing approximately 27.71% of the total issued share capital of Huakang Biomedical [1]. - Prior to the completion of the transaction, the offeror directly and beneficially owns 121 million shares, which is about 24.13% of the total issued share capital [1]. - Following the completion of the transaction, the offeror, Dr. Zhou, and any parties acting in concert with them will collectively own 259 million shares, representing approximately 51.84% of the total issued share capital [1]. Group 2 - The offeror is wholly owned by Dr. Zhou Xun Yong, who is also the sole director of the offeror [2]. - The company has applied to the Stock Exchange for the resumption of trading of its shares on GEM starting from 9:00 AM on October 10, 2025 [2].

香港交易及結算所有限公司及香港聯合交易所有限公司對本聯合公告的內容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 聯 合公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔 任 何 責 任。 本 聯 合 公 告 僅 供 參 考，並 不 構 成 收 購、購 買 或 認 購 華 康 生 物 醫 學 控 股 有 限 公 司 證 券 之 邀 請 或 要 約 或 構 成 其 一 部 分，或 於 任 何 司 法 權 區 招 攬 任 何 表 決 權 或 批 准，亦 不 得 在 與 適 用 法 律 法 規 相 抵 觸 之 情 況 下 於 任 何 司 法 權 區 出 售、發 行 或 轉 讓 華 康 生 物 醫 學 控 股 有 限 公 司 證 券。本 聯 合 公 告 不 會 在 構 成 違 反 有 關 司 法 權 區 相 關 法 律 的 情 況 下 於 或 向 任 何 司 法 權 區 發 佈、刊 發 或 派 發。 ANSELME LIMITED （於 英 屬 處 女 群 島 註 冊 成 立 之 有 限 公 司） HUAKANG BIOMED ...

Core Viewpoint - Huakang Biomedical (08622) has announced that its shares will be suspended from trading on the Hong Kong Stock Exchange's GEM starting from October 9, 2025, at 1 PM, pending the release of an announcement containing insider information in accordance with the Hong Kong Code on Takeovers and Mergers [1] Summary by Category - **Company Announcement** - Huakang Biomedical's shares will be suspended from trading on the Hong Kong Stock Exchange's GEM [1] - The suspension is effective from October 9, 2025, at 1 PM [1] - The suspension is due to the pending announcement of insider information [1] - **Regulatory Compliance** - The company is acting in accordance with the Hong Kong Code on Takeovers and Mergers [1]

Core Viewpoint - Huakang Biomedical (08622) has announced that its shares will be suspended from trading on the Hong Kong GEM starting from October 9, 2025, at 1:00 PM, pending the issuance of an announcement containing inside information in accordance with the Hong Kong Code on Takeovers and Mergers [1] Group 1 - The suspension of trading is a regulatory measure in response to the need for disclosure of inside information [1] - The announcement indicates potential significant developments regarding the company that may impact its stock performance [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 香港，二零二五年十月九日 應華康生物醫學控股有限公司（「本公司」）要求，本公司股份已自二零二五年十月九日（星 期四）下午一時正起於香港聯合交易所有限公司 GEM 暫停買賣，以待根據香港收購及合併 守則發出一份載有本公司之內幕消息之公告。 代表董事會 華康生物醫學控股有限公司 主席及執行董事 張玉靜 HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED 華康生物醫學控股有限公司 (於開曼群島註冊成立之有限公司) (股份代號: 8622) 短暫停牌 於本公告日期，執行董事為張玉靜女士、張春光先生及潘禮賢先生；非執行董事為卜素博士 及徐明博士；及獨立非執行董事為周國輝博士、王亞純女士及徐永得先生。 本公告的資料乃遵照《香港聯合交易所有限公司的 GEM 證券上市規則》而刊載，旨在提供有 關本公司的資料；董事願就本公告的資料共同及個別地承擔全部責任。各董事在作出一切合 理查詢後，確 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 華康生物醫學控股有限公司 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08622 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | 0.01 | HKD | | 10,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 1,000,000,000 | HKD | | 0.01 | HKD | | 10,000,000 | 本月底 ...

Group 1 - The core point of the article highlights that Huakang Biomedical (08622) has seen a significant stock deposit by shareholders into Zhonghao Securities, with a market value of HKD 49.5083 million, representing 24.13% of the total [1] - On August 15, Huakang Biomedical reported its financial results for the six months ending June 30, 2025, showing revenue of RMB 12.329 million, a year-on-year increase of 3.4% [1] - The company experienced a net loss of RMB 2.369 million, which is a 33.2% increase in losses compared to the previous year, with a basic loss per share of 0.47 cents [1] Group 2 - The increase in revenue is attributed to higher sales of male infertility in vitro diagnostic reagents and a series of parasitic testing reagents during the reporting period [1]